The mpox (monkeypox) virus is transmitted to humans through a bite or direct contact with an infected animal’s blood, body fluids or cutaneous/mucosal lesions.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 30 November - 6 December2024 and includes updates on increases in respiratory infections due to Mycoplasma pnemoniae in the EU/EEA, SARS-CoV-2 variant classification, Influenza A(H5N1), Avian influenza, Middle East respiratory syndrome, an unknown disease in the Democratic Republic of the Congo, mpox, suspected viral hemorrhagic fever in Sierra Leone, and overview of respiratory virus epidemiology in the EU/EEA.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 23-29 November 2024 and includes updates on the severe flood in Eastern Spain, HIV/AIDS surveillance, an overview of respiratory virus epidemiology in the EU/EEA, avian influenza A(H5N1), cholera, Mpox, and vaccine-derived poliovirus type 2.
The European Centre for Disease Prevention and Control (ECDC) is aware of the recent confirmation of the first mpox clade Ib case in Germany and is monitoring the situation closely. The case was acquired abroad and detected on Friday, 18 October 2024.
This report provides an overview of the total number of cases of mpox (monkeypox) reported to ECDC and the WHO Regional Office for Europe through IHR/EWRS mechanisms .
This issue of the CDTR covers the period 16-22 November 2024 and includes updates on chikungunya, dengue, avian influenza, West Nile virus, mpox, severe floods in eastern Spain, identification of cVDPV2 in sewage samples, and an overview of respiratory virus epidemiology in the EU/EEA.
MPXV has been detected in blood, urine, tissue abscesses and bodily fluids and could potentially be transmitted through SoHO. However, to date, there has been no reported transmission of MPXV through SoHO and the likelihood of this is unknown.
This reporting protocol is intended for reporting national case-based data for surveillance of mpox from all the countries and areas of the WHO European Region.
Rapid scientific advice to public health authorities in EU/EEA countries on how to prepare for and respond to mpox based on the currently available evidence.
